Trial reportBMC psychiatry2013
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
Trial report in BMC psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial.Neuropsychiatric disease and treatment · 2023Trial
- Hyperprolactinemia in Older Adults: A Narrative Review of Distinct Clinical Challenges and Management Strategies.Cureus · 2026Review
- Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2024Article
- Physical health monitoring for people with schizophrenia.Australian prescriber · 2023Review
- Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia.Neuropsychiatric disease and treatment · 2022Article
- Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015.European archives of psychiatry and clinical neuroscience · 2021Article
- Hyperprolactinemia in Adults with Prader-Willi Syndrome.Journal of clinical medicine · 2021Article
- Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review.CNS drugs · 2021Review
- Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia.British journal of clinical pharmacology · 2020Article
- Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia.Human psychopharmacology · 2020Article
- A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.BMC medical genetics · 2019Article
- Management of antipsychotic-induced hyperprolactinemia.The mental health clinician · 2016Article
- Chlorpromazine-Induced Hyperprolactinemia on Rat's Uterus.Iranian biomedical journal · 2015Article
- The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.CNS drugs · 2014Review
- Comparative Study of Extrapyramidal Side Effects, Sexual Dysfunctions and Hyperprolactinaemia Using Typical and Atypical Antipsychotic Medications Among Patients with Schizophrenia in Maiduguri.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.